Back to funds
View filing
Rosalind Advisors, Inc.
hedge fundUpdated 27 days agoManaged by Rosalind Advisors, Inc. • Latest filing Q2 2026
Portfolio value
$269.2M
Q2 2026
Filings
11
Quarterly 13F history
Top-10 concentration
98.9%
Weight of largest holdings
Annualized return
39.9%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 11 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2023 | $121.4M |
| Q1 2024 | $107M |
| Q2 2024 | $130M |
| Q3 2024 | $156.2M |
| Q4 2024 | $195.6M |
| Q1 2025 | $205.6M |
| Q2 2025 | $210.9M |
| Q3 2025 | $292.6M |
| Q4 2025 | $284.5M |
| Q1 2026 | $248.9M |
| Q2 2026 | $269.2M |
Top holdings
35 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | D DCTH DELCATH SYSTEMS, INC. | $41.6M | 3.30M | 15.44% | — |
| 2 | F FENC FENNEC PHARMACEUTICALS INC | $34.3M | 3.19M | 12.73% | — |
| 3 | X XERS XERIS BIOPHARMA HOLDINGS INC | $23M | 2.91M | 8.56% | — |
| 4 | S SVRA SAVARA INC | $19.6M | 3.18M | 7.27% | — |
| 5 | V VSTM VERASTEM INC | $15.2M | 3.99M | 5.66% | — |
| 6 | ? N/A X4 PHARMACEUTICALS INC | $15M | 3.21M | 5.58% | — |
| 7 | ? N/A EYEPOINT PHARMACEUTICALS INC | $14.1M | 988.2K | 5.25% | — |
| 8 | H HELP CYBIN INC | $12.9M | 1.96M | 4.80% | — |
| 9 | V VOR VOR BIOPHARMA INC | $11.9M | 648.6K | 4.44% | — |
| 10 | P PCVX VAXCYTE INC | $11.6M | 200.0K | 4.32% | — |
| 11 | M MDWD MEDIWOUND LTD | $11M | 749.1K | 4.09% | — |
| 12 | C CLDX CELLDEX THERAPEUTICS INC | $7.4M | 200.0K | 2.76% | — |
| 13 | B BCRX BIOCRYST PHARMACEUTICALS INC | $7.2M | 721.5K | 2.68% | — |
| 14 | P PROF PROFOUND MEDICAL CORP | $5.5M | 828.1K | 2.05% | — |
| 15 | ? N/A TALPHERA INC | $5.3M | 5.17M | 1.98% | — |
| 16 | A AVIR ATEA PHARMACEUTICALS INC | $5M | 1.07M | 1.85% | — |
| 17 | ? N/A MYOMO INC | $3.8M | 3.64M | 1.41% | — |
| 18 | O OVID OVID THERAPEUTICS INC | $3M | 1.11M | 1.11% | — |
| 19 | N NRXS NEURAXIS INC | $3M | 508.1K | 1.10% | — |
| 20 | A AAVXF ABIVAX SA | $2.8M | 20.9K | 1.03% | — |